New Research Sheds Light on Factors Influencing Medical Scheme Enrolment Decisions

By Staff Writer

July 24, 2023

The Council for Medical Schemes recently published an insightful study in the American Journal of Biomedical Science and Research titled ‘Profiling Dependants Joining Medical Schemes: An Analysis of Factors Influencing Enrolment Decisions.’

The study provides a fresh perspective in the ongoing debate between ‘medical aids’ and ‘cheap medical aid.’ From 2017 to 2021, an average of 1.1 million new dependants joined medical schemes each year, with newborns making up 23% and children under five accounting for 35%.

The authors suggest that by understanding enrolment decisions, medical schemes can tailor their strategies to the specific needs of dependants, potentially leading to higher enrolment rates and improved healthcare outcomes.

Enrolment in a medical scheme is a complex process influenced by multiple factors, including affordability, age, and healthcare needs.

Interestingly, in 2019, medical schemes collectively saw a high number of new dependants join the scheme at 1.3 million. However, in 2021, this number dropped to 622,000, likely due to the economic impact of COVID-19.

Closed schemes tend to enrol more new dependants below the age of 5, while open schemes typically enrol more beneficiaries aged 60 years.

The study also revealed that costs, availability of cost-sharing mechanisms, and financial incentives influence dependants’ decision to enrol in medical schemes.

To expand health insurance coverage, interventions should prioritize the healthcare needs of children and the elderly.

Reference url

Recent Posts

340B Drug Pricing Lawsuit
      

Lawsuits Challenge 340B Drug Pricing Program: Eli Lilly and J&J vs. HRSA

🤔 How will ongoing legal battles shape the future of the 340B Drug Pricing Program?

Eli Lilly and Johnson & Johnson are challenging HRSA’s proposed rebate models, arguing that their approaches are essential for enhancing transparency and ensuring discounts directly benefit vulnerable patients. This crucial legal dispute highlights the tensions surrounding drug pricing regulations and could profoundly impact how discounts are provided to covered entities.

Dive into the details of these lawsuits and their implications for the pharmaceutical landscape.

#SyenzaNews #pharmaceuticals #healthcarepolicy #innovation #DrugPricing

WHO Investment Round 2023
    

WHO Investment Round: Securing Funding with Transparency Challenges

🌍 How can global health initiatives thrive with increased funding?

The WHO Investment Round is a pivotal initiative striving to secure $7.1 billion for essential health programs from 2025 to 2028. While achieving 53% of this target via diverse donor engagement, transparency in funding remains a challenge. Discover how these efforts can accelerate progress towards universal health coverage and tackle critical health issues like malaria and cervical cancer!

#SyenzaNews #globalhealth #universalhealthcoverage #healthcare #innovation

HPV vaccination South Africa
    

HPV vaccination South Africa: Cervical Cancer Prevention

🌍 How is South Africa leading the charge against cervical cancer?

Since launching its HPV vaccination program, the country has made remarkable strides in protecting future generations. With impressive coverage rates and a focus on at-risk populations, South Africa serves as a global model for effective public health strategies. Discover how this initiative not only combats cervical cancer but also addresses broader health concerns.

#SyenzaNews #HealthTech #GlobalHealth #HealthcareInnovation #CervicalCancer #HPVVaccination

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2024 Syenza™. All rights reserved.